Research Article
Year 2021, Volume: 43 Issue: 3, 249 - 253, 30.09.2021
Abstract
Supporting Institution
Sivas Cumhuriyet Üniversitesi Bilimsel Araştırma Projeleri (CÜBAP)
References
- 1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds). WHO Classification of Tumours of the Central Nervous System. 4th ed, IARC, Lyon 2016. WHO
- 2. Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro Oncol 2018; 20 Suppl
- 3. Chang SM, Parney IF, Huang W, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005; 293: 557.
- 4. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Eng l J Med 2009; 360: 765. 5. Gokden M. If it is not Glioblastoma then What is it? A Differential Diagnostic Review. Adv Anat Pathol. 2017 Nov; 24 (6): 379-391. doi: 10.1097/PAP.0000000000000170.
- 6. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma Groups Basedon 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med 2015; 372: 2499.
- 7. Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencingas a basis foran "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma an dglioblastoma. ActaNeuropathol 2015; 129: 133.
- 8. Gramatzki D, Dehler S, Rushing EJ, et all. Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to2009. Cancer. 2016 Jul 15; 122 (14): 2206-2215. doi: 10.1002/cncr.30023. Epub2016 Apr18.
- 9. Wirsching HG, Galanis E,Weeler M. Glioblastoma. Handb Clin Neurol 2016; 134: 381-397. doi: 10.1016/B978-0-12-802997-8.00023-2
- 10. Wen PY, Weller M, Lee EQ, Alexander BM, et all. Glioblastoma in adults:a society for neuroOncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management anffd future directions. Neuro Oncol. 2020 Aug 17; 22 (8): 1073-1113. doi: 10.1093/neuonc/noaa106. PMID: 32328653.
- 11. Muir M, Gopakumar S, Traylor J, Lee S, Rao G. Glioblastoma multiforme: novel therapeutic targets. Expert Opin Ther Targets. 2020 Jul; 24 (7): 605-614. doi: 10.1080/14728222.2020.1762568.
Prognosis in IDH-Mutant and IDH-wild type glioblastoma
Year 2021, Volume: 43 Issue: 3, 249 - 253, 30.09.2021Abstract
Glioblastoma (GBM) is the most common brain tumor in adults with a poor prognosis and predominantly astrocytic differentiation. GBM is classified according to the isocitrate dehydrogenase (IDH) mutation according to the World Health Organization (WHO) Brain Tumors 2016 classification. IDH-1 gene mutations are evaluated immunohistochemically (IHC) and molecular methods in current pathology laboratory practice.
The aim of this study was to determine the overall survival in GBM cases according to IDH-1 mutation status and Ki-67 proliferation index.
Total of 53 patients diagnosed as GBM between 2007-2020 in Sivas Cumhuriyet University Faculty of Medicine, Department of Pathology were evaluated. Disease-free median survival of 7 (13%) GBM patients with IDH mutation was 2 months (2-year survival 14%), disease-free median survival 9 months (2-year survival 24 %) in GBM IDH-wild type cases. In cases with a higher Ki-67 proliferation index, the median disease-free survival were shorter.
In conclusion statistically significant results could not be obtained between disease-free survival in GBM IDH-mutant type and GBM IDH-wild type. However, the mean Ki-67 proliferation index of GBM IDH-wild type cases was found to be much higher than GBM IDH-mutant cases. High Ki-67 proliferation index was found to be associated with a significantly shorter survival.
References
- 1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds). WHO Classification of Tumours of the Central Nervous System. 4th ed, IARC, Lyon 2016. WHO
- 2. Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro Oncol 2018; 20 Suppl
- 3. Chang SM, Parney IF, Huang W, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005; 293: 557.
- 4. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Eng l J Med 2009; 360: 765. 5. Gokden M. If it is not Glioblastoma then What is it? A Differential Diagnostic Review. Adv Anat Pathol. 2017 Nov; 24 (6): 379-391. doi: 10.1097/PAP.0000000000000170.
- 6. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma Groups Basedon 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med 2015; 372: 2499.
- 7. Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencingas a basis foran "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma an dglioblastoma. ActaNeuropathol 2015; 129: 133.
- 8. Gramatzki D, Dehler S, Rushing EJ, et all. Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to2009. Cancer. 2016 Jul 15; 122 (14): 2206-2215. doi: 10.1002/cncr.30023. Epub2016 Apr18.
- 9. Wirsching HG, Galanis E,Weeler M. Glioblastoma. Handb Clin Neurol 2016; 134: 381-397. doi: 10.1016/B978-0-12-802997-8.00023-2
- 10. Wen PY, Weller M, Lee EQ, Alexander BM, et all. Glioblastoma in adults:a society for neuroOncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management anffd future directions. Neuro Oncol. 2020 Aug 17; 22 (8): 1073-1113. doi: 10.1093/neuonc/noaa106. PMID: 32328653.
- 11. Muir M, Gopakumar S, Traylor J, Lee S, Rao G. Glioblastoma multiforme: novel therapeutic targets. Expert Opin Ther Targets. 2020 Jul; 24 (7): 605-614. doi: 10.1080/14728222.2020.1762568.
Details
| Primary Language | English |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Surgical Science Research Articles |
| Authors |
|
| Project Number | T-902 |
| Publication Date | September 30, 2021 |
| Published in Issue | Year 2021Volume: 43 Issue: 3 |